Madrigal’s Rezdiffra tops $1B run-rate in MASH, but losses and rising GLP-1/FGF21 competition may cap upside into 2026. See ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback